PatientsVille.com Logo


Ritonavir Medical Research Studies

Up-to-date List of Ritonavir Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ritonavir Medical Research Studies

Rank Status Study
1 Recruiting Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Condition: Human Immunodeficiency Virus
Interventions: Drug: Atazanavir, Ritonavir, lamivudine;   Drug: Atazanavir, Ritonavir, 2 NRTIs
Outcome Measure: Proportion of patients with viral load < 50 copies/mL
2 Recruiting Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
Condition: HIV Infection
Intervention: Drug: atazanavir 300mg boosted with Ritonavir 50 mg
Outcome Measures: Pharmacokinetics;   adverse events
3 Recruiting Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Condition: HIV
Intervention: Drug: Lopinavir/Ritonavir 800 mg / 200mg
Outcome Measures: plasma viral load <40 copies/mL;   Stability in the plasma levels of Lopinavir/Ritonavir during all study visits;   Tolerability;   Adherence;   Satisfaction;   - Efficacy in CSF
4 Not yet recruiting Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Conditions: AIDS;   Tuberculosis
Intervention: Drug: Lopinavir/Ritonavir and Ritonavir
Outcome Measures: Proportion of patients with expected Cmax of rifampin.;   Proportion of patients with expected pre dose concentration of lopinavir.;   Proportion of patients with successful treatment of HIV therapy.;   Proportion of patients with expected AUC of rifampin;   Proportion of patient with success of tuberculosis therapy;   Proportion of patients with expected Cmax and AUC of lopinavir
5 Recruiting Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Ritonavir;   Procedure: therapeutic conventional surgery
Outcome Measures: Inhibition of breast cancer by targeting Hsp90-Akt pathway;   Activation of apoptosis markers;   Modulation of autophagy markers;   Alteration of plasma levels of eicosanoids;   Induction of Hsp70 in peripheral blood mononuclear cells;   Reduction of ERα in ERα+ tumors;   Changes in TNF-α and IL-6 levels as well as reduction in intratumoral nuclear NF-kB and phospho-Stat3;   Alteration of urine eicosanoid levels;   Alteration of plasma and urine eicosanoid levels resulting from tumor resection.;   Induction of the unfolded protein response (UPR) assayed by grp78 or related markers (phospho-PERK, ATF-4, and CHOP);   inhibition of tumor growth markers (Ki67 LI, Hsp90, phosphorylated AKT)
6 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir/Ritonavir, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: TMC114 (darunavir);   Drug: Ritonavir;   Drug: TMC125 (etravirine);   Drug: TMC278 (rilpivirine)
Outcome Measures: To assess the influence of pregnancy on the pharmacokinetics of darunavir/Ritonavir (darunavir/r) and/or etravirine and rilpivirine during the second and third trimesters of gestation, as well as postpartum;   Changes in anti-viral activity, safety and tolerability antiretroviral regimens during gestation and postpartum; compare concentrations between serum and cord blood; pregnancy outcome of darunavir/r and/or etravirine and rilpivirine
7 Unknown  Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
Condition: HIV-1 Infection
Intervention: Other: lopinavir/Ritonavir
Outcome Measure: assess the level of lopinavir trough level >1 mg/L in low dose lopinavir (reduction by 70%)
8 Recruiting Pharmacokinetic (PK) Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects With Undetectable Viral Load Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir-Containing Antiretroviral Therapy
Condition: HIV Infection
Intervention: Drug: Aprepitant
Outcome Measures: Inflammatory;   Safety;   Pharmacokinetic Cmin:;   Pharmacokinetic Cmax;   Pharmacokinetic Tmax;   Pharmacokinetic AUCss;   Inflammatory markers;   Lipids;   Neurological
9 Recruiting A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
Condition: Healthy Volunteer
Interventions: Drug: setrobuvir;   Drug: danoprevir;   Drug: Ritonavir
Outcome Measures: Safety: Incidence of adverse events;   Pharmacokinetics: Maximum plasma concentration at steady-state (Css,max);   Pharmacokinetics: Total area under the concentration-time curve form time 0 to 12 hours post-dose at steady-state (AUCss,0-12h);   Pharmacokinetics: Plasma concentration at steady-state 12 hours post-dose (Css, 12h);   Pharmacokinetics: Time to maximum plasma concentration (tmax);   Pharmacokinetics: Elimination half-life (t1/2);   Pharmacokinetics: Apparent oral clearance at steady-state (CLss/F);   Pharmacokinetics: Cumulative amount excreted at steady-state (Aess);   Pharmacokinetics: Fraction of orally administered drug excreted into urine (fe/f);   Pharmacokinetics of danoprevir in combination with setrobuvir: Area under the concentration-time curve (AUC);   Pharmacokinetics of Ritonavir in combination with setrobuvir: Area under the concentration-time curve (AUC)
10 Unknown  Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
Conditions: HIV-1 Adults Patients;   AIDS;   Triple Class Failure
Interventions: Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/Ritonavir
Outcome Measures: Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24;   Proportion of patients with HIV RNA levels of less than 50 copies/ml at week 24 and with HIV RNA levels of less than 400 copies/ ml at weeks 24 and 48.
11 Recruiting Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Conditions: HIV;   Hepatitis C;   Liver Fibrosis
Interventions: Drug: Raltegravir;   Drug: Ritonavir-boosted protease inhibitor
Outcome Measures: To evaluate the effect of switch on change in liver fibrosis score;   To evaluate inflammatory markers associated with liver fibrosis;   To evaluate effect of switch on hepatic function;   To evaluate effect of switch on metabolic parameters;   Immunologic and virologic safety
12 Recruiting A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
Condition: Chronic Hepatitis C
Interventions: Drug: TMC647055;   Drug: TMC435;   Drug: Ritonavir;   Drug: Ribavirin;   Drug: Pegylated interferon alpha-2a (PegIFN);   Drug: GSK2336805
Outcome Measures: Number of patients with a sustained virologic response (SVR) 12 Weeks after the actual end of treatment;   Number of patients with adverse events;   Number of patients with a sustained virological response (SVR at 4 and/or 24 Weeks after the actual end of treatment);   HCV RNA levels over time;   Number of patients with undetectable hepatitis C virus (HCV) RNA (less than 25 IU/mL undetectable) and/or HCV RNA levels less than 25 IU/mL at all time points;   Number of patients with on-treatment virologic failure;   Number of patients with viral relapse;   Number of patients with presence of HCV variants associated with reduced susceptibility to investigational treatment;   Maximum plasma analyte concentration of TMC435;   Minimum plasma analyte concentration of TMC435;   Area under the plasma concentration-time curve of TMC435;   Maximum plasma analyte concentration of TMC647055;   Minimum plasma analyte concentration of TMC647055;   Area under the plasma concentration-time curve of TMC647055;   Maximum plasma analyte concentration of Ritonavir (RTV);   Minimum plasma analyte concentration of RTV;   Area under the plasma concentration-time curve of RTV;   Minimum and maximum plasma concentrations of GSK233680k;   Area under the plasma concentration-time curve of GSK233680k
13 Not yet recruiting Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
Conditions: HIV Infection;   Osteopenia
Interventions: Drug: raltegravir and atazanavir and Ritonavir;   Drug: tenofovir/emtricitabine and atazanavir and Ritonavir
Outcome Measures: Variations from baseline in DEXA-measured bone mineral density (t-score, spine and femur);   variations from baseline in CTX (C-terminal telopeptide of type I collagen) and OC (Osteocalcin);   To assess the variation in renal function
14 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: Ritonavir;   Radiation: radiation therapy
Outcome Measures: Time to treatment failure in the brain (TTF) as determined by the radiological response rate;   Overall survival (OS);   Radiological volumetric response to treatment;   Local intracranial disease progression at 4 months;   Progression-free survival at 6 months;   Improvement of symptoms;   Time to symptom relapse or symptom progression;   Duration of use of steroids;   Duration of use of anticonvulsive drugs
15 Recruiting The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers
Condition: HIV
Interventions: Drug: Ritonavir;   Drug: Cobicistat
Outcome Measures: To characterize dabigatran pharmacokinetics alone and in combination with Ritonavir or cobicistat, respectively, using 2 different dosing strategies, in healthy volunteers.;   To characterize dabigatran pharmacodynamics (as measured by ECT) alone and in combination with RTV or COBI, respectively, using 2 different dosing strategies in healthy volunteers
16 Unknown  Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: LPV/r
Outcome Measures: plasma concentration level;   toxicity;   CD4;   HIV RNA;   genotypic resistant
17 Unknown  Atazanavir and Lamivudine for Treatment Simplification
Condition: HIV Infections
Interventions: Drug: Lamiduvine (Epivir);   Drug: Atazanavir (Reyataz);   Drug: Ritonavir (Norvir)
Outcome Measures: proportion of patients with virological failure (two consecutive measures of HIV-RNA higher than 50 copies/mL or a single measure higher than 1000 copies/mL) within 48 weeks at intention-to.treat analysis;   Time to virological failure at survival analysis;   Proportion of patients with viral load lower than 50 copies/mL at 48 weeks at the intention to treat analysis;   Evolution of CD4 cell count during the 48 weeks;   Evolution of adherence and quality of life during the 48 weeks;   Evolution of atazanavir plasma concentrations during the 48 weeks;   Change of metabolic parameters at 48 weeks;   Change of the results of neurocognitive tests at 48 weeks;   Change of bone density and of subcutaneous fat at 48 weeks
18 Not yet recruiting DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
Condition: HIV/AIDS
Interventions: Drug: BMS-663068;   Drug: Darunavir (DRV);   Drug: Ritonavir (RTV);   Drug: Etravirine (ETR)
Outcome Measures: Maximum observed plasma concentration (Cmax) of BMS-626529;   Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529;   Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR;   Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR;   Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR;   Cmax for DRV, RTV, and ETR;   AUC(TAU) for DRV, RTV, and ETR;   Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs
19 Unknown  Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: LPV/r;   Drug: Nucleoside Reverse Transcriptase Inhibitors;   Drug: PEG-IFNa 2a;   Drug: Ribavirin
Outcome Measures: To assess if the combination of LPV/r monotherapy in association with;   anti-HCV therapy (PEG IFN alfa 2a + Ribavirin) does not match with additional;   toxicity induced by the combination of optimized HAART (Lopinavir/Ritonavir + selected Nucs) and PEG-IFN alfa 2a+Ribavirin;   in patients naïve for HIV and HCV;   To assess if LPV/r monotherapy during the HCV treatment;   is associated with anti HIV efficacy and a better patient satisfaction;   vs optimized HAART.
20 Unknown  Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Condition: Atazanavir
Interventions: Drug: atazanavir;   Drug: Atazanavir(ATZ) and Tenofovir(TDF);   Drug: Atazanavir(ATZ) + Ritonavir;   Drug: atazanavir(ATZ) + tenofovir(TDF) + Ritonavir
Outcome Measures: Pharmacokinetic analysis;   Pharmacokinetic evaluation

These studies may lead to new treatments and are adding insight into Ritonavir etiology and treatment.

A major focus of Ritonavir research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Ritonavir